The Scripps Research Institute's Department of Molecular Therapeutics was established at the Scripps Florida campus in 2007. The department focuses on chemical biology approaches to dissecting signaling pathways and transcriptional programs, using state-of-the-art, multi-disciplinary technology and methodology and a variety of model systems for target identification, validation and pre-clinical studies.
Investigators within the department have created strong research programs in a wide range of therapeutic areas such as glaucoma, Parkinson's disease, diabetes, obesity, addiction, and cancer. Many of these programs take advantage of the unique technologies available at Scripps Florida, including high throughput genomic screening, high throughput small molecule screening, and state-of-the-art proteomic technology.
Because many of the molecular targets studied within the department are modulated by endogenous ligands, the department seeks to discover and develop small molecules that activate or repress these targets and these small molecules may be the foundation for novel therapeutics.